Rituximab provides durable remission in a patient with refractory aggressive diffuse B-cell lymphoma failing salvage chemotherapy

Eric Robach, Celaletin Ustun, Andre Kallab, Russel E. Burgess, Anand P. Jillella

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The outcome of patients with aggressive refractory diffuse large B-cell lymphoma (DLCL) is generally poor. A 43-year-old female with DLCL, who relapsed after first line chemotherapy (CHOP-cyclophosphamide, doxorubicin, vincristine, and prednisone) and progressed despite salvage chemotherapy (EPOCH-etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin), was treated effectively with 8 cycles of Rituximab. She is without evidence of disease with a follow-up of 32 months. We report this case to bring to attention the possibility of sustained durable remission with single agent Rituximab in refractory DLCL.

Original languageEnglish (US)
Pages (from-to)2235-2236
Number of pages2
JournalLeukemia and Lymphoma
Volume43
Issue number11
DOIs
StatePublished - Nov 1 2002
Externally publishedYes

Fingerprint

Lymphoma, Large B-Cell, Diffuse
B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Vincristine
Prednisone
Drug Therapy
Doxorubicin
Cyclophosphamide
Etoposide
Rituximab

Keywords

  • Diffuse large B-cell lymphoma
  • Lymphoma
  • Rituxan
  • Rituximab

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Rituximab provides durable remission in a patient with refractory aggressive diffuse B-cell lymphoma failing salvage chemotherapy. / Robach, Eric; Ustun, Celaletin; Kallab, Andre; Burgess, Russel E.; Jillella, Anand P.

In: Leukemia and Lymphoma, Vol. 43, No. 11, 01.11.2002, p. 2235-2236.

Research output: Contribution to journalArticle

Robach, Eric ; Ustun, Celaletin ; Kallab, Andre ; Burgess, Russel E. ; Jillella, Anand P. / Rituximab provides durable remission in a patient with refractory aggressive diffuse B-cell lymphoma failing salvage chemotherapy. In: Leukemia and Lymphoma. 2002 ; Vol. 43, No. 11. pp. 2235-2236.
@article{bd2194569239420580da27a2fc2aa980,
title = "Rituximab provides durable remission in a patient with refractory aggressive diffuse B-cell lymphoma failing salvage chemotherapy",
abstract = "The outcome of patients with aggressive refractory diffuse large B-cell lymphoma (DLCL) is generally poor. A 43-year-old female with DLCL, who relapsed after first line chemotherapy (CHOP-cyclophosphamide, doxorubicin, vincristine, and prednisone) and progressed despite salvage chemotherapy (EPOCH-etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin), was treated effectively with 8 cycles of Rituximab. She is without evidence of disease with a follow-up of 32 months. We report this case to bring to attention the possibility of sustained durable remission with single agent Rituximab in refractory DLCL.",
keywords = "Diffuse large B-cell lymphoma, Lymphoma, Rituxan, Rituximab",
author = "Eric Robach and Celaletin Ustun and Andre Kallab and Burgess, {Russel E.} and Jillella, {Anand P.}",
year = "2002",
month = "11",
day = "1",
doi = "10.1080/1042819021000016131",
language = "English (US)",
volume = "43",
pages = "2235--2236",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - Rituximab provides durable remission in a patient with refractory aggressive diffuse B-cell lymphoma failing salvage chemotherapy

AU - Robach, Eric

AU - Ustun, Celaletin

AU - Kallab, Andre

AU - Burgess, Russel E.

AU - Jillella, Anand P.

PY - 2002/11/1

Y1 - 2002/11/1

N2 - The outcome of patients with aggressive refractory diffuse large B-cell lymphoma (DLCL) is generally poor. A 43-year-old female with DLCL, who relapsed after first line chemotherapy (CHOP-cyclophosphamide, doxorubicin, vincristine, and prednisone) and progressed despite salvage chemotherapy (EPOCH-etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin), was treated effectively with 8 cycles of Rituximab. She is without evidence of disease with a follow-up of 32 months. We report this case to bring to attention the possibility of sustained durable remission with single agent Rituximab in refractory DLCL.

AB - The outcome of patients with aggressive refractory diffuse large B-cell lymphoma (DLCL) is generally poor. A 43-year-old female with DLCL, who relapsed after first line chemotherapy (CHOP-cyclophosphamide, doxorubicin, vincristine, and prednisone) and progressed despite salvage chemotherapy (EPOCH-etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin), was treated effectively with 8 cycles of Rituximab. She is without evidence of disease with a follow-up of 32 months. We report this case to bring to attention the possibility of sustained durable remission with single agent Rituximab in refractory DLCL.

KW - Diffuse large B-cell lymphoma

KW - Lymphoma

KW - Rituxan

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=0036838242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036838242&partnerID=8YFLogxK

U2 - 10.1080/1042819021000016131

DO - 10.1080/1042819021000016131

M3 - Article

C2 - 12533055

AN - SCOPUS:0036838242

VL - 43

SP - 2235

EP - 2236

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 11

ER -